این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
Iranian Journal of Blood and Cancer، جلد ۲، شماره ۲، صفحات ۶۱-۶۶
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی Effects of Recombinant Urate Oxidase (Rasburicase) and Allopurinol for Prophylaxis and Treatment of Hyperuricemia in Patients with Leukemia and Lymphoma
چکیده انگلیسی مقاله Background: Efficacy of rasburicase in pediatric patients with leukemia and lymphoma is proved. This study aims toweigh efficacy and safety of rasburicase versus more conventional therapy, allopurinol, and to compare their safetyand properties in tumor lysis syndrome (TLS) of leukemia and lymphoma patients.Materials and Methods: The study was done with a retrospective cohort design. Patients were selected from ourhematology ward admitted from 2005 through 2008. Patients were put into two groups based on their blood levelsof uric acid, before initiation of chemotherapy treatment group (the Uric Acid level of 6.5 mg/dl or more) and theprophylaxis group (the uric acid level below 6.5 mg/dl). Evaluation of effectiveness of therapy was performed after24, 48, 72-hour, and longer periods.Results: Of 184 patients 69% had leukemia, and 31% lymphoma. Twenty patients were treated with rasburicaseand 164 with allopurinol. Mean age of patients was 7.93± 4.247 years old. 60.8% were male and 39.2% were female.According to Chi-square test results, there was no significant difference between two agents regarding prophylaxis(chi-square = 4.247, p-value = 0.193) and treatment (chi-square = 0.780, p-value = 0.677). Most of the response toeach agent was seen in the first 24 hours after drug administration. Mean level of uric acid reduced from 7.4 to 3.4mg/dl in rasburicase, and from 5.4 to 3.9 mg/dl in allopurinol group. Mean duration of treatment for rasburicase was2 days, and for allopurinol 6 days. Adverse effects were minimal in both groups (in rasburicase 1.6% and in allopurinol5.4%).Conclusion: Rasburicase seems to be highly efficient in both prophylaxis and treatment of Hyperuricemia. Due tohigh costs in our practice, it was only administered to 20 patients with high levels of blood uric acid or leukocytosis.It prepares patients for chemotherapy faster and decreases cost of hospital stay indirectly by lowering cost oftreatment. Allopurinol, alternatively showed equal efficiency and comparable results. Thus, it can be used safely andeffectively until rasburicase becomes more widely available and more cost-effective.
کلیدواژه‌های انگلیسی مقاله Hyperuricemia, Rasburicase, Allopurinol, Leukemia, Lymphoma
نویسندگان مقاله خدیجه ارجمندی | khadijeh arjmandi
hematology oncology center, aliasghar children hospital, tehran university of medical sciences. tehran, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی تهران (Tehran university of medical sciences)

رضا تقی پور | reza taghipor
hematology oncology center, aliasghar children hospital, tehran university of medical sciences. tehran, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی تهران (Tehran university of medical sciences)

مریم تشویقی | maryam tashvighi
azad islamic university, ghom, iran.

سازمان اصلی تایید شده: دانشگاه علوم پزشکی تهران (Tehran university of medical sciences)

دانیال جعفری | danial jafari
hematology oncology center, aliasghar children hospital, tehran university of medical sciences. tehran, iran.

سازمان اصلی تایید شده: دانشگاه علوم پزشکی تهران (Tehran university of medical sciences)

نشانی اینترنتی http://www.ijbc.ir/browse.php?a_code=A-10-2-171&slc_lang=en&sid=en
فایل مقاله فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده en
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده 1
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات